Multicellular factor analysis of single-cell data for a tissue-centric understanding of disease

Abstract

Biomedical single-cell atlases describe disease at the cellular level. However, analysis of this data commonly focuses on cell-type centric pairwise cross-condition comparisons, disregarding the multicellular nature of disease processes. Here we propose multicellular factor analysis for the unsupervised analysis of samples from cross-condition single-cell atlases and the identification of multicellular programs associated with disease. Our strategy, which repurposes group factor analysis as implemented in multi-omics factor analysis, incorporates the variation of patient samples across cell-types or other tissue-centric features, such as cell compositions or spatial relationships, and enables the joint analysis of multiple patient cohorts, facilitating the integration of atlases. We applied our framework to a collection of acute and chronic human heart failure atlases and described multicellular processes of cardiac remodeling, independent to cellular compositions and their local organization, that were conserved in independent spatial and bulk transcriptomics datasets. In sum, our framework serves as an exploratory tool for unsupervised analysis of cross-condition single-cell atlases and allows for the integration of the measurements of patient cohorts across distinct data modalities.

Data availability

The datasets and computer code produced in this study are available in the following databases:-All scripts related to this manuscript can be consulted here: https://github.com/saezlab/MOFAcell.-The R package implementing multicellular factor analysis can be found in:https://github.com/saezlab/MOFAcellulaR-The python implementation of multicellular factor analysis is available here:https://liana-py.readthedocs.io/en/latest/notebooks/mofacellular.html-A Zenodo entry containing data associated to this manuscript can be accessed here: https://zenodo.org/record/8082895.

The following previously published data sets were used

Article and author information

Author details

  1. Ricardo Omar Ramirez Flores

    Faculty of Medicine, Heidelberg University, Heidelberg, Germany
    For correspondence
    roramirezf@uni-heidelberg.de
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0087-371X
  2. Jan David Lanzer

    Faculty of Medicine, Heidelberg University, Heidelberg, Germany
    Competing interests
    No competing interests declared.
  3. Daniel Dimitrov

    Faculty of Medicine, Heidelberg University, Heidelberg, Germany
    Competing interests
    No competing interests declared.
  4. Britta Velten

    Centre for Organismal Studies, Heidelberg University, Heidelberg, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8397-3515
  5. Julio Saez-Rodriguez

    Faculty of Medicine, Heidelberg University, Heidelberg, Germany
    For correspondence
    pub.saez@uni-heidelberg.de
    Competing interests
    Julio Saez-Rodriguez, reports funding from GSK, Pfizer and Sanofi and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Pfizer and Grunenthal..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8552-8976

Funding

DFG CRC 1550 (464424253)

  • Ricardo Omar Ramirez Flores
  • Julio Saez-Rodriguez

Informatics for Life

  • Jan David Lanzer
  • Julio Saez-Rodriguez

EU ITN Marie Curie StrategyCKD (860329)

  • Daniel Dimitrov
  • Julio Saez-Rodriguez

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jihwan Park, Gwangju Institute of Science and Technology, Republic of Korea

Version history

  1. Preprint posted: February 23, 2023 (view preprint)
  2. Received: October 5, 2023
  3. Accepted: November 14, 2023
  4. Accepted Manuscript published: November 22, 2023 (version 1)
  5. Version of Record published: December 13, 2023 (version 2)

Copyright

© 2023, Ramirez Flores et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,242
    views
  • 369
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ricardo Omar Ramirez Flores
  2. Jan David Lanzer
  3. Daniel Dimitrov
  4. Britta Velten
  5. Julio Saez-Rodriguez
(2023)
Multicellular factor analysis of single-cell data for a tissue-centric understanding of disease
eLife 12:e93161.
https://doi.org/10.7554/eLife.93161

Share this article

https://doi.org/10.7554/eLife.93161

Further reading

    1. Computational and Systems Biology
    2. Evolutionary Biology
    Ryan T Bell, Harutyun Sahakyan ... Eugene V Koonin
    Research Article

    A comprehensive census of McrBC systems, among the most common forms of prokaryotic Type IV restriction systems, followed by phylogenetic analysis, reveals their enormous abundance in diverse prokaryotes and a plethora of genomic associations. We focus on a previously uncharacterized branch, which we denote coiled-coil nuclease tandems (CoCoNuTs) for their salient features: the presence of extensive coiled-coil structures and tandem nucleases. The CoCoNuTs alone show extraordinary variety, with three distinct types and multiple subtypes. All CoCoNuTs contain domains predicted to interact with translation system components, such as OB-folds resembling the SmpB protein that binds bacterial transfer-messenger RNA (tmRNA), YTH-like domains that might recognize methylated tmRNA, tRNA, or rRNA, and RNA-binding Hsp70 chaperone homologs, along with RNases, such as HEPN domains, all suggesting that the CoCoNuTs target RNA. Many CoCoNuTs might additionally target DNA, via McrC nuclease homologs. Additional restriction systems, such as Type I RM, BREX, and Druantia Type III, are frequently encoded in the same predicted superoperons. In many of these superoperons, CoCoNuTs are likely regulated by cyclic nucleotides, possibly, RNA fragments with cyclic termini, that bind associated CARF (CRISPR-Associated Rossmann Fold) domains. We hypothesize that the CoCoNuTs, together with the ancillary restriction factors, employ an echeloned defense strategy analogous to that of Type III CRISPR-Cas systems, in which an immune response eliminating virus DNA and/or RNA is launched first, but then, if it fails, an abortive infection response leading to PCD/dormancy via host RNA cleavage takes over.

    1. Computational and Systems Biology
    Skander Kazdaghli, Iordanis Kerenidis ... Philip Teare
    Research Article

    Imputing data is a critical issue for machine learning practitioners, including in the life sciences domain, where missing clinical data is a typical situation and the reliability of the imputation is of great importance. Currently, there is no canonical approach for imputation of clinical data and widely used algorithms introduce variance in the downstream classification. Here we propose novel imputation methods based on determinantal point processes (DPP) that enhance popular techniques such as the multivariate imputation by chained equations and MissForest. Their advantages are twofold: improving the quality of the imputed data demonstrated by increased accuracy of the downstream classification and providing deterministic and reliable imputations that remove the variance from the classification results. We experimentally demonstrate the advantages of our methods by performing extensive imputations on synthetic and real clinical data. We also perform quantum hardware experiments by applying the quantum circuits for DPP sampling since such quantum algorithms provide a computational advantage with respect to classical ones. We demonstrate competitive results with up to 10 qubits for small-scale imputation tasks on a state-of-the-art IBM quantum processor. Our classical and quantum methods improve the effectiveness and robustness of clinical data prediction modeling by providing better and more reliable data imputations. These improvements can add significant value in settings demanding high precision, such as in pharmaceutical drug trials where our approach can provide higher confidence in the predictions made.